secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOVIE INC. (BIVI)
CIK:        0001580149
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0001520138-23-000511
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioVie Phase 3 NE3107 Alzheimer's trial misses primary endpoint; positive per-protocol trends
--------------------------------------------------------------------------------

- Primary endpoint missed statistical significance due to exclusion of patients from 15 sites with GCP violations; sites referred to FDA.
- Per-protocol analysis (57 patients) showed NE3107 cognitive and functional improvement vs placebo comparable to approved monoclonal antibodies.
- NE3107-treated patients had 4.66-year age deceleration advantage vs placebo via Horvath DNA methylation clock.
- Company plans to work with FDA on adaptive design to continue enrolling patients toward statistical significance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580149/000152013823000511/0001520138-23-000511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580149/000152013823000511/bivi-20231129_8k.htm
  HTML page:      https://secwatch.observer/filing/0001520138-23-000511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer